Camp4 Therapeutics Corp (CAMP) is a pre-revenue clinical-stage biopharmaceutical company with no approved products and a $310.5M accumulated deficit as of March 31, 2026. Under a liquidation lens, recovery to equity is negative on any reasonable construct. Liquidatable assets are dominated by cash and cash equivalents of $99.2M (100% recovery) plus restricted cash of $1.6M, yielding approximately $100.8M in high-confidence liquid asset recovery. PP&E net book value is $1.9M gross (before haircut), but at a 50-60% haircut on $10.2M gross with $8.3M accumulated depreciation, realizable value is de minimis, roughly $0.9-1.2M. Prepaid expenses of $2.3M recover at near-zero under liquidation; intangible/IP assets are not separately carried on the balance sheet and carry zero recovery value. Total haircutted asset recovery is approximately $101-102M. Against this, total liabilities at face value are $74.6M, composed of: current liabilities of $16.6M (accounts payable $0.9M, accrued liabilities $4.3M, deferred revenue-current $11.1M, operating lease current $0.4M); noncurrent liabilities of $57.9M dominated by the derivative tranche liability of $50.9M (Level 3, Monte Carlo-valued, representing the forward obligation on the Second Closing of the September 2025 private placement) plus noncurrent deferred revenue $5.2M and noncurrent operating lease $1.7M. The derivative tranche liability is the critical liability-side variable: it increased $6.2M QoQ from $44.8M at December 31, 2025 to $50.9M at March 31, 2026, driven by an increase in the probability of achieving the Second Closing conditions from 25% to 45%. Under a strict liquidation lens this liability does not extinguish at zero — its treatment in wind-up is uncertain (it is a freestanding derivative, not a funded debt obligation), but at face value it absorbs approximately half of liquid asset recovery. Net liquidation surplus to equity is approximately $101M minus $74.6M = approximately $26M, before any wind-down costs, severance, or advisor fees. The MFFAIS CLV/LLV/OLV of $80.8M reflects a cash-heavy but liability-burdened structure. Cash burn for Q1 2026 was $11.0M operating, implying roughly 9 quarters of runway from current cash at this rate, consistent with management's guidance of sufficiency into 2028. The Watertown Lease had not commenced as of March 31, 2026, so no ROU asset or liability is yet recognized for that 44,000 sq ft commitment through June 2030 — that unrecognized future obligation (with a $2.1M modification fee payable in installments plus contracted Watertown rents) represents contingent off-balance-sheet liability exposure not captured in the face-value liability stack. Filing discusses the Watertown Lease commencement obligation and the $2.1M lease modification fee in MD&A and footnotes but these are not separately XBRL-tagged as future minimum payment commitments beyond what appears in the current operating lease maturity schedule (which covers only the Boulder Lease, per the $2.2M total disclosed).
▼ Community Notes